Cost, access, treatment burden, and a lack of high-quality data may explain why apheresis is seldom used to lower lipoprotein ...

When you think about cholesterol—if you think about it at all—your mind probably jumps to its effect on your heart disease risk, particularly if your doctor has said your levels aren’t where they ...

Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not been fully ...

The European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study is part of the largest prospective evaluation of diet and health ever undertaken. The entire EPIC study involves ...

While drugs are available that reduce levels of lipoprotein (a), a protein associated with cardiovascular disease, no currently available therapies target this protein directly. Several companies are ...

Please provide your email address to receive an email when new articles are posted on . A combination of obicetrapib and ezetimibe further lowered LDL in statin-treated patients with dyslipidemia. A ...

SINGAPORE, Sept. 24, 2025 /PRNewswire/ -- Cardiovascular disease (CVD) kills nearly 18 million people every year, more than all cancers combined, yet one of its critical genetic risk factors remains ...